Clinical research
It was a busy week for clinical trial news. Here’s a look.
Multiple pharma company stocks make their first appearance on the Nasdaq this morning to advance the next-generation therapeutics. BioSpace takes a look at some of these IPOs.
The Oncologic Drugs Advisory Committee (ODAC), as part of the U.S. Food and Drug Administration (FDA), has voted 13-to-4 against supporting the accelerated approval of Incyte’s PD-1 inhibitor for squamous cell carcinoma.
Roche had a big week, scoring wins but also stepping away from its gene therapy partnership with 4D Molecular Therapeutics.
The first interim analysis of a three-arm Phase II ARC-7 trial shows Arcus Biosciences’ anti-TIGIT immunotherapy combination features “encouraging clinical activity” as an initial therapy for patients with metastatic non-small cell lung cancer (NSCLC).
The company said it will file a marketing application later this year for the drug under the FDA’s accelerated approval pathway.
The U.S. FDA has had a mix of announcements this week, from drug approvals to the acceptance of NDAs and INDs. Here’s a look.
The decision to exercise the option was based on an interim analysis of the ongoing Phase I trial of TNB-383B.
Fulcrum achieved what the company is calling a clinical first. Data showed that using losmapimod slowed the progression of FSHD and demonstrated improved function in patients.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES